Skip to main content
Erschienen in: BMC Cancer 1/2017

Open Access 01.12.2017 | Research article

Gene expression, regulation of DEN and HBx induced HCC mice models and comparisons of tumor, para-tumor and normal tissues

verfasst von: Qin Tang, Qi Wang, Qiong Zhang, Sheng-Yan Lin, Yanhong Zhu, Xiangliang Yang, An-Yuan Guo

Erschienen in: BMC Cancer | Ausgabe 1/2017

Abstract

Background

Hepatocellular carcinoma (HCC) is the leading cause of cancer mortality. Chemical and virus induction are two major risk factors, however, the potential molecular mechanisms of their differences remain elusive. In this study, to identify the similarities and differences between chemical and virus induced HCC models, we compared the gene expression profiles between DEN and HBx mice models, as well as the differences among tumor, para-tumor and normal tissues.

Methods

We sequenced both gene and microRNA (miRNA) expression for HCC tumor tissues, para-tumor and normal liver tissues from DEN model mice (30-week-old) and downloaded the corresponding microarray expression data of HBx model from GEO database. Then differentially expressed genes (DEGs), miRNAs and transcription factors (TFs) were detected by R packages and performed functional enrichment analysis. To explore the gene regulatory network in HCC models, miRNA and TF regulatory networks were constructed by target prediction.

Results

For model comparison, although DEGs between tumor and normal tissues in DEN and HBx models only had a small part of overlapping, they shared common pathways including lipid metabolism, oxidation-reduction process and immune process. For tissue comparisons in each model, genes in oxidation-reduction process were down-regulated in tumor tissues and genes in inflammatory response showed the highest expression level in para-tumor tissues. Genes highly expressed in both tumor and para-tumor tissues in two models mainly participated in immune and inflammatory response. Genes expressed in HBx model were also involved in cell proliferation and cell migration etc. Network analysis revealed that several miRNAs such as miR-381-3p, miR-142a-3p, miR-214-3p and TFs such as Egr1, Atf3 and Klf4 were the core regulators in HCC.

Conclusions

Through the comparative analyses, we found that para-tumor tissue is a highly inflammatory tissue while the tumor tissue is specific with both inflammatory and cancer signaling pathways. The DEN and HBx mice models have different gene expression pattern but shared pathways. This work will help to elucidate the molecular mechanisms underlying different HCC models.
Hinweise

Electronic supplementary material

The online version of this article (doi: 10.​1186/​s12885-017-3860-x) contains supplementary material, which is available to authorized users.
Abkürzungen
DEGs
Differentially expressed genes
DEN
Diethylnitrosamine
HBx
Hepatitis B virus X antigen
HCC
Hepatocellular carcinoma
miRNA
MicroRNA
TF
Transcription factor

Background

Hepatocellular carcinoma (HCC) accounts for 85 - 90% of liver malignancies and is the second cause of cancer death in the world [1]. Although many progresses have been achieved on HCC research, it still needs a better understanding of the molecular and regulatory mechanisms involved in HCC [2]. HCC is often arisen by several risk factors including hepatitis virus B or C (HBV or HCV) infection, chemical damage and chronic excessive alcohol intake and so on [3]. The occurrence of HBV induced HCC attributes to HBV proliferation and DNA integration into host genome to initiate the malignant proliferation and transformation [4]. The HBx (HBV regulatory x protein) of hepatitis B virus plays a crucial role in hepatocarcinogenesis by transcriptional activation, driving deregulated cell cycle progression, modulation of apoptosis and inhibition of nucleotide excision repair of damaged cellular DNA [5]. While chemical induced HCC leads to high levels of DNA damage and fails to block the cell cycle before the damaged DNA repaired [6]. In recent years, chemical-induced and virus-induced HCC mouse models are widely used for the studies of pathogenesis and drug treatment of HCC [6, 7]. However, the differences of gene expression and regulation in these two HCC models have not been compared, which is an important issue for model selection in HCC studies.
Diethylnitrosamine (DEN), a DNA alkylating agent, is widely used to induce liver cancer in rodent model with high success rate and similarity to human HCC [8]. Recently, DEN-induced rodent HCC models have been used to investigate the pathogenesis, prevention and treatment of liver cancer, which include evaluating miRNA functions, exploring the antitumor effects of drugs and identifying biomarkers and therapeutic targets etc. [9, 10]. HBx is a 154-amino acid hepatitis B viral protein which controls the level of HBV replication [11]. As early as 1991, Kim, et al. constructed transgenic mouse model harboring HBx gene and firstly found this gene can specifically induce liver cancer [12]. Lu, et al. used HBx to induce HCC in transgenic male C57 mice and identified some common regulators in HCC [13]. Ye, et al. studied the synergistic function of Kras mutation and HBx in mice HCC [14].
In recent years, microRNAs (miRNAs) and transcription factors (TFs) have drawn extensive attention in cancer research. They play pivotal roles in proliferation, differentiation, invasion and metastasis of tumors. Many miRNAs were reported as important regulators in HCC. For example, miR-221 promotes human HCC development and its silencing contributes to suppressing tumor properties [15]. MiR-214 and miR-375 suppress the proliferation of HCC cells by directly targeting E2F3 and AEG-1 respectively [16, 17]. TFs are paramount regulators in controlling gene expression in living organisms [18]. For example, PPARs contribute to the pathogenesis in cell cycling, anti-inflammatory responses and apoptosis [19]. Aberrant high expression of STAT3 may promote HCC migration and invasion [20]. To further explore the molecular mechanisms in complex diseases, regulatory networks are widely studied. Our previous studies have revealed the miRNA and TF co-regulatory motifs are pervasive regulatory models in biological processes and diseases [18, 2123]. Through network analysis, the complex regulatory relationships in diseases will be illuminated on systematic level and the key regulators may be identified.
In this study, we applied bioinformatic approaches to analyze the high-throughput and microarray data of DEN and HBx HCC mice models. We aim to analyze the gene expression features and core regulatory factors in HCC from these two models, and reveal the similarities and differences between them as well as compare gene expression profiles in tumor, para-tumor and normal tissues in each model.

Methods

Sequencing of DEN model and data collection of HBx model

All of the experimental mice were male and purchased from Hubei Research Center of Laboratory Animals (Wuhan, China) and in the C57 genetic background. To induce HCC in mice, we used DEN as the inductive agent. In this study, all mice were divided into two groups: DEN group and control group. In DEN group, mice were fed with basal diet every day and given DEN treatment at a dose of 165 mg per kg body weight in sesame oil through oral once a week for 10 weeks, then drug treatment were stopped and the mice were fed with diet only until 30 weeks. In control group, mice were fed with basal diet only until 30 weeks. In order to determine whether the liver tissues have suffered cancerous changes, histopathologic examinations were conducted via microscope (Additional file 1: Figure S1). All of the animal procedures were performed in accordance with the Ethics Committee on Animal Experimentation of the Huazhong University of Science and Technology (Wuhan, China) and the NIH Guide for the Care and Use of Laboratory Animals (8th edition, 2011).
To detect gene and miRNA expression, high-throughput sequencing technologies were used: RNA-seq for detection of expressed transcripts and small RNA-seq for detection of miRNAs respectively. Samples of tumor and para-tumor liver tissues were excised from the same lobe of the liver. For control group, RNA was isolated from liver samples obtained from age-matched healthy mice. Three biological replicates were sequenced for each group. For RNA-seq, ribosome RNA was removed first and pair-end 150 bp sequencing were carried out through Illumina Hiseq 3000, while for small RNA-seq, single-end 50 bp sequencing were performed with Illumina Hiseq 2500. All of the sequencing and data filtering works were done by Ribobio company (Guangzhou, China).
The microarray expression data of HBx model were downloaded from Gene Expression Omnibus (GEO) (http://​www.​ncbi.​nlm.​nih.​gov/​geo/​, GEO accession: GSE15251). This model used Hepatitis B virus X antigen (HBx) to induce HCC in transgenic male C57 mice. The microarray samples of tumor, para-tumor and normal tissues were from the 16-month-old mice and the experimental conditions were similar with our DEN model.

Gene expression and differential expression analysis among tumor, para-tumor, and normal tissues

In DEN model, RNA-seq reads were firstly quality-checked by fastqc software, then HISAT2 (version: 2.0.5) was used for mapping sequencing reads to mouse genome GRCm38, and StringTie (version: 1.2.2) was used to assemble the RNA-seq alignments into potential transcripts based on the reference sequences and calculate the abundance of transcripts [24]. The expressed levels were estimated as FPKM (the number of Fragments (reads) per kilobase of transcript per million mapped reads). The differentially expressed genes (DEGs) were identified using NOISeq [25] with thresholds FDR < 0.01 and |fold-change| ≥ 1.5. For small RNA-seq, firstly reads were aligned to the mouse genome, mouse miRNA and miRNA precursor data using Bowtie2 [26], then the expression of miRNAs were estimated as RPM (reads per million mapped reads). The differential expression of miRNAs were calculated by DEGseq [27] and edgeR [28], the threshold was also set as |fold change| ≥ 1.5 and required their RPM ≥ 20 in at least one tissue. Results of two methods were pooled together subsequently. In HBx model, DEGs were identified by NOIseq with FDR < 0.01 and |fold-change| ≥ 4.0.
The expression characteristics of two models were displayed by cumulative distribution function plot. The definition of cumulative distribution function is: Fx(x) = P(X ≤ x), where the right-hand side represents the probability that the random variable X takes on a value less than or equal to x [29]. And the top 5% expressed genes were extracted for function enrichment and comparison. To survey the functions of genes, we used DAVID (https://​david.​ncifcrf.​gov/​tools.​jsp) for GO (gene ontology) and KEGG (Kyoto Encyclopedia of Genes and Genomes) enrichment analysis. The top ranked enrichment results with high significant levels (p-value <0.01) were selected for discussion and presented by bubble plots using R package ‘ggplot2’. In the bubble plot, rich factor is calculated as the ratio of gene counts that mapped to a certain pathway and the total gene number of that pathway.
To reveal the gene expression difference between tumor and non-tumor tissues in two models, the pairwise comparisons of DEGs were carried out among tumor, para-tumor and normal tissue. Venn diagrams of DEGs were drawn and pathway enrichment in each model were implemented as described above.

Gene function comparison between DEN model and HBx model

To further compare similarities and differences between two models, we firstly analyzed the similarities and differences between tumor tissue in DEN model and HBx model, and then focused on the para-tumor tissues of two models. The common pathways in two models were shown by bar charts, and the different pathways were exhibit by bubble plots. What’s more, heatmaps were used to recognize the gene expression patterns among three tissues.

Identification of miRNA and TF targets and construction of regulatory networks

Networks were constructed using the differentially expressed data by reference to the collected validated data from several databases. For miRNA, we collected experimentally verified targets as described in our previous review paper [22]. The data mainly include the overlapped results from miRWalk2, miRecords4, miRTarbase6 and Tarbase7. TF targets were extracted from TRANSFAC database. The regulatory interactions between miRNA/TF and genes were obtained via Python script. Finally Cytoscape (Version 3.2.1) were used to visualize the networks.

Results

The cumulative distribution of genes in DEN and HBx models and functions of highly expressed genes in tumor

In this study, a total of 20,901 genes were detected by high-throughput sequencing in DEN model, and 23,855 genes were identified in HBx model microarray data. To investigate the relationship between the increasing ratio of gene numbers and the gene expression level, the cumulative distributions of genes in two models are shown in Fig. 1a. In each model, three distribution curves represent different distributions of tumor, para-tumor and normal tissues respectively. The left-side of the dotted vertical line represents the cumulative distribution of 95% genes in that model, while the right-side represents the cumulative distribution of the top 5% high expressed genes. In DEN model, the log10 (FPKM) of 95% genes are less than 1.43 while in HBx model the log10 (fluorescence value) of 95% genes are less than 3.94. On the whole, these two models exhibit different characteristics of gene distribution: the distribution range of gene expression in DEN model is relatively narrow and sharp increasing, while the distribution range of gene expression in HBx model is relatively wide and slow increasing. This may due to the difference of gene expression platform (RNA-seq and microarray).
To investigate the functions of the key genes in two models, the comparison of top 5% highly expressed genes of the corresponding tissues in two models were carried out (Fig. 1b). The two models have an overlap of 500, 459 and 435 highly expressed genes in normal, para-tumor and tumor tissues respectively. Genes in tumor tissues may be directly related to the pathogenesis of HCC, so more attention was paid to the comparison of these genes in two models. Through biology process and KEGG pathway enrichment analysis, the common and different functions were identified. The top five shared processes and pathways were complement and coagulation cascades, acute-phase response, hemostasis, oxidation-reduction process and metabolism especially lipid metabolism (Fig. 1c). The top ranked specific pathways in tumor tissues of DEN model are oxidative phosphorylation, non-alcoholic fatty liver disease (NAFLD), antigen processing and presentation of exogenous peptide antigen. While in HBx model, sterol biosynthetic process, cell-cell adhesion and triglyceride homeostasis were obtained (Additional file 2).

Gene expression difference among tumor, para-tumor, and normal tissues in both models

To compare the gene expression between tumor and non-tumor tissues in two models, the pairwise comparisons of DEGs were performed among tumor, para-tumor and normal tissues. The statistical results of up- and down-regulated genes in each model were shown in Fig. 2. Firstly, we focused on the functions of up- and down-regulated DEGs in tumor vs normal tissues in two models. The comparison results revealed that the up-regulated genes of tumor vs normal tissue in DEN model were mainly involved in immune response, acute-phase response, cholesterol and triglyceride homeostasis (Fig. 2a). While genes in down-regulated group of DEN model were involved in oxidation-reduction process, metabolic pathways such as cholesterol and steroid metabolic process (Fig. 2b). In HBx model, the up-regulated genes of tumor vs normal tissue were (Fig. 2c) mainly involved in positive regulation of gene expression, cell adhesion, cell proliferation, cell migration, cell cycle, wound healing, immune response. But in down-regulated group of HBx model (Fig. 2d), genes were also involved in metabolic pathways and oxidation-reduction process, which are similar to DEN model. For the comparison between para-tumor and normal tissue, up-regulated genes in para-tumor in both models were enriched in immune and inflammatory response which suggested the para-tumor tissues were in high inflammatory status. The functional enrichment results of other comparisons were also shown in Fig. 2.
To further investigate gene expression differences among three tissues in two models, we recognized the gene expression patterns and found 6 clusters in each model (Fig. 3). Genes with highest expression in normal tissue (Cluster1 in Fig. 3a and b) mainly involved in oxidation-reduction process and lipid metabolic process. Genes in Cluster2 of Fig. 3a and b were in the highest expression in para-tumor tissue. The common function of these genes in both models is inflammatory response, while the specific function in DEN model includes immune process and in HBx model concludes gland development and morphogenesis. The pattern of the highest expression in tumor tissue were recognized in Cluster3 of Fig. 3a and b. The same functions of this pattern in two models include immune process, inflammatory response and metabolic process especially sterol, cholesterol and steroid metabolism. What’s more, we also focused on the genes highly expressed in both tumor and para-tumor tissues (Cluster4 in Fig. 3a, Cluster4 and Cluster5 in Fig. 3b), these genes mainly participated in immune system process, inflammatory response, phagocytosis, cell cycle and several cancer pathways.
From the above results, we could summarize that the healthy liver tissue is mainly characterized with lipid biosynthetic and metabolic process and oxidation-reduction on account of maintenance the normal life activities, while the tumor tissue is characterized with immune, inflammatory response and cancer pathways. The immune effect and inflammatory response in para-tumor tissue are higher than normal tissue. What’s more, these responses also show a slight declined trend in tumor tissue when compared with para-tumor tissues. Therefore, we suggest that the para-tumor tissue should be regarded as inflammatory tissue rather than normal tissue.

Functional comparison of DEGs between DEN and HBx models

To disclose the similarities and differences of gene functions between two models, we further focused on tumor tissues and para-tumor tissues in two models. The DEGs of tumor vs normal tissue and para-tumor vs normal tissue were regarded as the specific genes of tumor tissue and para-tumor tissue, respectively. As a result, we found the DEN and HBx models only shared a small part of tumor specific genes (Fig. 4a). Further, we compared their gene functions and found 9 common functional terms (Fig. 4c). The top ranked common pathways of tumor tissues were oxidation-reduction process, metabolic processes especially lipid, cholesterol and steroid metabolic processes. There are also dozens of different enriched pathways in DEN and HBx models (Additional file 1: Figure S2 a). In tumor tissue of HBx model, the most significant different pathways are retinol metabolism, wound healing, positive regulation of gene expression and positive regulation of protein kinase B signaling, while in DEN model, the most significant different pathway is chemical carcinogenesis. Although only a few para-tumor genes shared by two models (Fig. 4b), functional enrichment analysis indicated 10 shared pathways (Fig. 4d), top of which is immune response. There are also dozens of different enriched pathways (Additional file 1: Figure S2 b). In para-tumor tissue of HBx model, the most significant different pathway is phagocytosis, while in DEN model the most significant different pathways are response to interferon-gamma and the negative regulation of neuron death.

Differentially expressed miRNAs and its regulatory network in DEN model

To explore the miRNA expression and their regulation to genes in HCC, we sequenced the miRNA in the DEN model. We totally obtained 28 differentially and highly expressed miRNAs (Fig. 5a) from the pairwise comparisons of three tissues. Most of the miRNAs showed the highest expression level in para-tumor tissue and the lowest level in normal tissue, but their differences were not significant by comparing tumor and para-tumor tissues. To explain this phenomenon we conducted immunohistochemistry experiments to quantify the proteins of two miRNA produced genes, DROSHA and ADAR. The results showed that the highest expression of these two proteins were shown in para-tumor tissue, while the lowest expression level indicated in normal tissue (Additional file 1: Figure S3 a), and their variation trends were consistent with the RNA-seq data (Additional file 1: Figure S3 b). The top ten highly expressed miRNAs (ranked by the mean expression value of three tissues) are miR-199a-3p, miR-199a-5p, miR-146a-5p, miR-146b-5p, miR-125a-5p, miR-200a-3p, miR-200b-3p, miR-142a-5p, miR-486b-5p and miR-182-5p.
To recognize the molecular regulation mechanism in HCC, a miRNA-gene regulation network was constructed in DEN model. Firstly, we found out a total of 186 genes that show opposite expression tendency with miRNAs. Then regulatory relationships between the miRNAs and genes were screened out according to verified miRNA targets which collected from several databases. Finally 98 regulatory pairs were obtained and intergrated into a network containing 17 miRNAs and 50 genes with 98 edges (Fig. 6a). In this network, the top three significant miRNAs with most targets were miR-381-3p, miR-142a-3p, miR-214-3p, which may be the important regulatory factors in DEN HCC. It was reported that miR-381 was up-regulated in mouse liver and acted as a hub regulators [30], miR-142-3p can suppresses the migration and invasion of HCC cells by regulating RAC1 [31], and miR-214 can suppress invasion, stem-like traits and recurrence of HCC through targeting beta-catenin pathway [32]. Our results were not only in accordance with these reports, but also revealed some synergistic regulations.

Differentially expressed TFs and its regulatory network in HBx model

For the HBx model, although we have no corresponding miRNA data, we can identify the differnetially expressed TFs and explore the TF regulatory network. From the DEGs we obtained 15 highly expressed TFs (Fig. 5b). The regulatory relationships between 15 TFs and 524 genes were screened out and presented in a network (Fig. 6b). This network included a total of 539 nodes and 938 edges. Obviously, it is creditable to recongize that the TFs Egr1, Atf3 and Klf4 are the main regulatory factors in this model. The importance of these TFs have been verified by previous studies. It was reported that EGR-1 can inhibit the growth of hepatocellular carcinoma cell lines and suppress the transformation activity in fibrosarcoma and breast carcinoma [33], ATF3 and KLF4 were reported as tumor suppressors in HCC [34, 35]. Subnetworks of these TFs are listed in Additional file 1: Figure S4. Through enrichment analysis, we found that the targets of these TFs mainly participated in cell adhesion, proliferation, migration, apoptotic and multiple cancer signaling pathways such as PI3K-Akt, MAPK, Ras and p53 signalling pathway, which are important pathways in HCC.
To investigate the synergistic regulations on oncogenes and tumor suppressor genes (TSGs) of TFs, we collected the oncogenes and TSGs in HCC from previous publications [36, 37]. We found that 5 of these genes were in the TF regulatory network (Fig. 6b) and a sub-network containing the 5 genes and 7 TFs was extracted to exhibit the synergistic regulations (Fig. 6c). From the network, we found both the TSG Tgfbr2 and Socs3 can be co-regulated by tumor suppressor Egr1 and Atf3, while the TSG Cdkn1a is the most significant gene which can be co-regulated by 5 TFs (Egr1, Atf3, Klf4, Vdr and Ar). TSG Lgals3 can be co-regulated by Atf3 and Ar.

Discussion

In this study, we investigated the highly expressed genes in both DEN and HBx mice models, and identified the DEGs through comparison among tumor, para-tumor and normal tissues. The gene expression profiles and function enrichment of different tissues demonstrate different characteristics and functional specificities of three tissues. Moreover, through comparison of two models, we found both similarities and differences exited in gene expression. Finally, we constructed miRNA and TF regulatory networks and identified several key regulators from the networks, as well as revealed some synergistic regulations in HCC models.
Through comparison of tumor, para-tumor and normal tissues, we suggest that para-tumor liver tissues should be regarded as inflammatory tissue rather than normal tissue. But in the study of human solid carcinomas, due to the sampling limitations, researchers usually use comparison of tumor and adjacent non-tumor tissues of patients to illustrate the molecular mechanism of cancers. In fact, from our study, the maximal effects of immune responses and inflammatory responses were detected in para-tumor tissues rather than tumor tissues or normal tissues. While the normal tissues were characterized with lipid mechanism and oxidation-reduction, and the tumor tissues enriched in cancer signal transduction, immune and inflammatory responses (Figs. 2 and 3). Till to now, only a few articles have reported the comparisons among three tissues. Chandran et al. investigated the gene expression differences among prostate cancer tissue, adjacent prostate cancer tissue and normal prostate tissue from cancer free organ donors. They found that the tumor vs normal expression profile was more extensive than the tumor vs adjacent normal profile, when using normal as the baseline, similar genes were up-regulated in both tumor and adjacent tissue, and these genes can not be identified from tumor vs adjacent normal profile [38]. In other words, para-tumor tissue is somewhat similar to tumor tissue. Also in this study, the tumor and para-tumor tissues emerged with higher response of inflammatory and immune than normal tissues, which was in agreement with previous report that inflammation was closely related to cancer. Grivennikov and Karin reported that about 20% of all cancers generated in association with chronic inflammation, and most of the solid tumors contain proinflammatory cytokines which can mediate immune responses and effect tumor initiation, growth and progression [39].
In previous studies, both DEN- and HBx-induced mice liver cancer models have been used to investigate the pathogenesis of HCC, they have become the two major concerns in liver cancer research [9, 10, 13]. It has been verified that the cancers of DEN and HBx induced in mice are very similar to human HCC [8, 40]. Comparison of these two representative models can accurately reveal the mechanism of HCC carcinogenesis. But so far, no studies have investigated the difference of molecular mechanisms between drug-induced and virus-induced HCC. Through comparison of the same tissues between two models, we found that immune response, inflammatory responses, metabolic process, and oxidation-reduction process are the common activities in both two models. There are also several different enriched pathways in two models. The most significant different pathway in DEN model is chemical carcinogenesis while in HBx model they are retinol metabolism, wound healing, positive regulation of gene expression and positive regulation of protein kinase B signaling pathway. These differences may due to the different induction of two model (DEN and HBx). Another obviously difference is that the HBx model appears with more cancer related activities, for example, cell signal transduction and communication, cell cycle and programmed cell death. This may due to the long/short period of induction. DEN induction is more acute and can resulted in serious injury even death before all the cancer pathways significantly emerged, while HBx induction is chronic and mice can live longer until all the cancer pathways obviously emerged. It was reported that signaling molecules such as EGFR, Ras, PKC, AKT/PKB and mTOR, were found to play important roles in human cancer cells and were involved in cell proliferation, differentiation and survival [41]. PDCD4 (Programmed Cell Death Protein4) gene can be inhibited by miRNA-21 and results in the failure of programmed cell death, and finally enhances cell proliferation in HCC and breast cancer [42, 43]. These molecules or their subtypes were also found highly expressed in the models in this study.
At the same time, we also identified differentially expressed miRNAs and TFs from the data, and constructed two major regulatory networks. From network analysis, miR-381-3p, miR-142a-3p, miR-214-3p and Egr1, Atf3, Klf4 were identified to be the most important regulators in HCC. These are important tumor suppressors which can be considered as diagnosis biomarkers and treatment targets. What’s more, the synergistic regulation analysis indicated that Cdkn1a is the most import target gene of multiple TFs in HCC (Fig. 6c). It can encode a potent cyclin-dependent kinase inhibitor and inhibits the activities of several cyclin-cyclin-dependent kinases, not only functions as a regulator of cell cycle progression at the G1 pahse, but also involved in the regulation of transcription, apoptosis, DNA repair and cell motility [44]. Previous study has reported that the expression of this gene is tightly controlled by the tumor suppressor protein p53 [45]. In this study, we found it was also synchronously regulated by the TFs Egr1, Atf3, Klf4, Vdr and Ar, this result enriched the recognition of regulatory mechanisms of this gene. Besides, the TSG Tgfbr2 is also a top ranked gene that was synchronously regulated by multiple TFs. Tgfbr2 is a key molecule in TGFbeta signaling pathway and was found to prevent the formation of hepatocellular carcinomas and cholangiocarcinoma development [46]. Taken together, through network analysis we identified several pivotal regulators and cancer related genes, this work provided comprehensive information for gene regulation involved in HCC.

Conclusions

Through gene expression and function analyses, we found that both DEN and HBx model shared common pathways including lipid metabolism, oxidation-reduction process, immune process and inflammatory responses. Through tissue comparison, we suggest that the para-tumor should be recognized as inflammatory tissue. Network analysis revealed that miRNAs such as miR-381-3p, miR-142a-3p, miR-214-3p and TFs such as Egr1, Atf3 and Klf4 are the hub regulators in HCC. These results will help to increase understanding of molecular mechanisms of HCC.

Acknowledgements

Not applicable.

Funding

This project was supported by fundings from the National Natural Science Foundation of China (No. 31471247), National Basic Research Program of China (973 Program, 2012CB932501), and Open Project funded by Key laboratory of Carcinogenesis and Translational Research, Ministry of Education/Beijing (2017 Open Project- 6).

Availability of data and materials

The DEN datasets generated during the current study are not publicly available due to data and privacy protection considerations but may be available on justified request. The expression matrix for HBx model (3 samples) were downloaded from the Gene Expression Omnibus (GEO) (GEO accession: GSE15251).
All of the animal procedures were performed in accordance with the ethics committee on animal experimentation of the Huazhong University of Science and Technology (Wuhan, China), and the procedures complied with the NIH guide for the care and use of laboratory animals (8th edition, 2011).
Not applicable.

Competing interests

All authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.
Literatur
1.
Zurück zum Zitat Lafaro KJ, Demirjian AN, Pawlik TM. Epidemiology of hepatocellular carcinoma. Surg Oncol Clin N Am. 2015;24:1–17.CrossRefPubMed Lafaro KJ, Demirjian AN, Pawlik TM. Epidemiology of hepatocellular carcinoma. Surg Oncol Clin N Am. 2015;24:1–17.CrossRefPubMed
2.
Zurück zum Zitat Bosetti C, Turati F, La Vecchia C. Hepatocellular carcinoma epidemiology. Best Pract Res Clin Gastroenterol. 2014;28:753–70.CrossRefPubMed Bosetti C, Turati F, La Vecchia C. Hepatocellular carcinoma epidemiology. Best Pract Res Clin Gastroenterol. 2014;28:753–70.CrossRefPubMed
3.
Zurück zum Zitat Marengo A, Rosso C, Bugianesi E. Liver cancer: connections with obesity, fatty liver, and cirrhosis. Annu Rev Med. 2016;67:103–17.CrossRefPubMed Marengo A, Rosso C, Bugianesi E. Liver cancer: connections with obesity, fatty liver, and cirrhosis. Annu Rev Med. 2016;67:103–17.CrossRefPubMed
4.
Zurück zum Zitat Kremsdorf D, Soussan P, Paterlini-Brechot P, Brechot C. Hepatitis B virus-related hepatocellular carcinoma: paradigms for viral-related human carcinogenesis. Oncogene. 2006;25:3823–33.CrossRefPubMed Kremsdorf D, Soussan P, Paterlini-Brechot P, Brechot C. Hepatitis B virus-related hepatocellular carcinoma: paradigms for viral-related human carcinogenesis. Oncogene. 2006;25:3823–33.CrossRefPubMed
6.
7.
Zurück zum Zitat Schmidt J, Jo M, Zhou T, Kim Y, MacLeod AR. Abstract 4359: characterization of GalNAc-conjugated generation 2.5 ASOs in DEN and DEN/CCL4-induced HCC tumors. Cancer Res. 2015;75:4359.CrossRef Schmidt J, Jo M, Zhou T, Kim Y, MacLeod AR. Abstract 4359: characterization of GalNAc-conjugated generation 2.5 ASOs in DEN and DEN/CCL4-induced HCC tumors. Cancer Res. 2015;75:4359.CrossRef
8.
Zurück zum Zitat Chang W, He W, Li PP, Song SS, Yuan PF, Lu JT, et al. Protective effects of Celastrol on diethylnitrosamine-induced hepatocellular carcinoma in rats and its mechanisms. Eur J Pharmacol. 2016;784:173–80.CrossRefPubMed Chang W, He W, Li PP, Song SS, Yuan PF, Lu JT, et al. Protective effects of Celastrol on diethylnitrosamine-induced hepatocellular carcinoma in rats and its mechanisms. Eur J Pharmacol. 2016;784:173–80.CrossRefPubMed
9.
Zurück zum Zitat Jo W, Yu ES, Chang M, Park HK, Choi HJ, Ryu JE, et al. Metformin inhibits early stage diethylnitrosamineinduced hepatocarcinogenesis in rats. Mol Med Rep. 2016;13:146–52.CrossRefPubMed Jo W, Yu ES, Chang M, Park HK, Choi HJ, Ryu JE, et al. Metformin inhibits early stage diethylnitrosamineinduced hepatocarcinogenesis in rats. Mol Med Rep. 2016;13:146–52.CrossRefPubMed
10.
Zurück zum Zitat Marrone AK, Shpyleva S, Chappell G, Tryndyak V, Uehara T, Tsuchiya M, et al. Differentially expressed MicroRNAs provide mechanistic insight into fibrosis-associated liver carcinogenesis in mice. Mol Carcinog. 2016;55:808–17.CrossRefPubMed Marrone AK, Shpyleva S, Chappell G, Tryndyak V, Uehara T, Tsuchiya M, et al. Differentially expressed MicroRNAs provide mechanistic insight into fibrosis-associated liver carcinogenesis in mice. Mol Carcinog. 2016;55:808–17.CrossRefPubMed
11.
Zurück zum Zitat Tu T, Budzinska MA, Shackel NA, Jilbert AR. Conceptual models for the initiation of hepatitis B virus-associated hepatocellular carcinoma. Liver Int. 2015;35:1786–800.CrossRefPubMed Tu T, Budzinska MA, Shackel NA, Jilbert AR. Conceptual models for the initiation of hepatitis B virus-associated hepatocellular carcinoma. Liver Int. 2015;35:1786–800.CrossRefPubMed
12.
Zurück zum Zitat Kim CM, Koike K, Saito I, Miyamura T, Jay G. HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature. 1991;351:317–20.CrossRefPubMed Kim CM, Koike K, Saito I, Miyamura T, Jay G. HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature. 1991;351:317–20.CrossRefPubMed
13.
Zurück zum Zitat Lu JW, Hsia Y, Yang WY, Lin YI, Li CC, Tsai TF, et al. Identification of the common regulators for hepatocellular carcinoma induced by hepatitis B virus X antigen in a mouse model. Carcinogenesis. 2012;33:209–19.CrossRefPubMed Lu JW, Hsia Y, Yang WY, Lin YI, Li CC, Tsai TF, et al. Identification of the common regulators for hepatocellular carcinoma induced by hepatitis B virus X antigen in a mouse model. Carcinogenesis. 2012;33:209–19.CrossRefPubMed
14.
Zurück zum Zitat Ye H, Zhang C, Wang BJ, Tan XH, Zhang WP, Teng Y, et al. Synergistic function of Kras mutation and HBx in initiation and progression of hepatocellular carcinoma in mice. Oncogene. 2014;33:5133–8.CrossRefPubMed Ye H, Zhang C, Wang BJ, Tan XH, Zhang WP, Teng Y, et al. Synergistic function of Kras mutation and HBx in initiation and progression of hepatocellular carcinoma in mice. Oncogene. 2014;33:5133–8.CrossRefPubMed
15.
Zurück zum Zitat He XX, Guo AY, Xu CR, Chang Y, Xiang GY, Gong J, et al. Bioinformatics analysis identifies miR-221 as a core regulator in hepatocellular carcinoma and its silencing suppresses tumor properties. Oncol Rep. 2014;32:1200–10.CrossRefPubMed He XX, Guo AY, Xu CR, Chang Y, Xiang GY, Gong J, et al. Bioinformatics analysis identifies miR-221 as a core regulator in hepatocellular carcinoma and its silencing suppresses tumor properties. Oncol Rep. 2014;32:1200–10.CrossRefPubMed
16.
Zurück zum Zitat Yang Y, Chang S, Zhao Z, Hou NI, He K, Wang X, et al. MicroRNA-214 suppresses the proliferation of human hepatocellular carcinoma cells by targeting E2F3. Oncol Lett. 2015;10:3779–84.PubMedPubMedCentral Yang Y, Chang S, Zhao Z, Hou NI, He K, Wang X, et al. MicroRNA-214 suppresses the proliferation of human hepatocellular carcinoma cells by targeting E2F3. Oncol Lett. 2015;10:3779–84.PubMedPubMedCentral
17.
Zurück zum Zitat He XX, Chang Y, Meng FY, Wang MY, Xie QH, Tang F, et al. MicroRNA-375 targets AEG-1 in hepatocellular carcinoma and suppresses liver cancer cell growth in vitro and in vivo. Oncogene. 2012;31:3357–69.CrossRefPubMed He XX, Chang Y, Meng FY, Wang MY, Xie QH, Tang F, et al. MicroRNA-375 targets AEG-1 in hepatocellular carcinoma and suppresses liver cancer cell growth in vitro and in vivo. Oncogene. 2012;31:3357–69.CrossRefPubMed
18.
Zurück zum Zitat Lin Y, Zhang Q, Zhang HM, Liu W, Liu CJ, Li Q, et al. Transcription factor and miRNA co-regulatory network reveals shared and specific regulators in the development of B cell and T cell. Sci Rep. 2015;5:15215.CrossRefPubMedPubMedCentral Lin Y, Zhang Q, Zhang HM, Liu W, Liu CJ, Li Q, et al. Transcription factor and miRNA co-regulatory network reveals shared and specific regulators in the development of B cell and T cell. Sci Rep. 2015;5:15215.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Zhang N, Duan WD, Leng JJ, Zhou L, Wang X, Xu YZ, et al. STAT3 regulates the migration and invasion of a stemlike subpopulation through microRNA21 and multiple targets in hepatocellular carcinoma. Oncol Rep. 2015;33:1493–8.CrossRefPubMed Zhang N, Duan WD, Leng JJ, Zhou L, Wang X, Xu YZ, et al. STAT3 regulates the migration and invasion of a stemlike subpopulation through microRNA21 and multiple targets in hepatocellular carcinoma. Oncol Rep. 2015;33:1493–8.CrossRefPubMed
21.
Zurück zum Zitat Zhang H-M, Li Q, Zhu X, Liu W, Hu H, Liu T, et al. miR-146b-5p within BCR-ABL1–positive microvesicles promotes leukemic transformation of hematopoietic cells. Cancer Res. 2016;76:2901–11.CrossRefPubMed Zhang H-M, Li Q, Zhu X, Liu W, Hu H, Liu T, et al. miR-146b-5p within BCR-ABL1–positive microvesicles promotes leukemic transformation of hematopoietic cells. Cancer Res. 2016;76:2901–11.CrossRefPubMed
22.
Zurück zum Zitat Zhang HM, Kuang S, Xiong X, Gao T, Liu C, Guo AY. Transcription factor and microRNA co-regulatory loops: important regulatory motifs in biological processes and diseases. Brief Bioinform. 2015;16:45–58.CrossRefPubMed Zhang HM, Kuang S, Xiong X, Gao T, Liu C, Guo AY. Transcription factor and microRNA co-regulatory loops: important regulatory motifs in biological processes and diseases. Brief Bioinform. 2015;16:45–58.CrossRefPubMed
23.
Zurück zum Zitat Ye H, Liu X, Lv M, Wu Y, Kuang S, Gong J, et al. MicroRNA and transcription factor co-regulatory network analysis reveals miR-19 inhibits CYLD in T-cell acute lymphoblastic leukemia. Nucleic Acids Res. 2012;40:5201–14.CrossRefPubMedPubMedCentral Ye H, Liu X, Lv M, Wu Y, Kuang S, Gong J, et al. MicroRNA and transcription factor co-regulatory network analysis reveals miR-19 inhibits CYLD in T-cell acute lymphoblastic leukemia. Nucleic Acids Res. 2012;40:5201–14.CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Pertea M, Kim D, Pertea GM, Leek JT, Salzberg SL. Transcript-level expression analysis of RNA-seq experiments with HISAT, StringTie and Ballgown. Nat Protoc. 2016;11:1650–67.CrossRefPubMedPubMedCentral Pertea M, Kim D, Pertea GM, Leek JT, Salzberg SL. Transcript-level expression analysis of RNA-seq experiments with HISAT, StringTie and Ballgown. Nat Protoc. 2016;11:1650–67.CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Tarazona S, Garcia-Alcalde F, Dopazo J, Ferrer A, Conesa A. Differential expression in RNA-seq: a matter of depth. Genome Res. 2011;21:2213–23.CrossRefPubMedPubMedCentral Tarazona S, Garcia-Alcalde F, Dopazo J, Ferrer A, Conesa A. Differential expression in RNA-seq: a matter of depth. Genome Res. 2011;21:2213–23.CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Wang L, Feng Z, Wang X, Wang X, Zhang X. DEGseq: an R package for identifying differentially expressed genes from RNA-seq data. Bioinformatics. 2010;26:136–8.CrossRefPubMed Wang L, Feng Z, Wang X, Wang X, Zhang X. DEGseq: an R package for identifying differentially expressed genes from RNA-seq data. Bioinformatics. 2010;26:136–8.CrossRefPubMed
28.
Zurück zum Zitat Robinson MD, McCarthy DJ, Smyth GK. edgeR: a bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26:139–40.CrossRefPubMed Robinson MD, McCarthy DJ, Smyth GK. edgeR: a bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26:139–40.CrossRefPubMed
29.
Zurück zum Zitat Zwillinger D, Kokoska S. CRC standard probability and statistics tables and formulae. 1999. Crc Press. Zwillinger D, Kokoska S. CRC standard probability and statistics tables and formulae. 1999. Crc Press.
30.
Zurück zum Zitat Hsu SD, Huang HY, Chou CH, Sun YM, Hsu MT, Tsou AP. Integrated analyses to reconstruct microRNA-mediated regulatory networks in mouse liver using high-throughput profiling. BMC Genomics. 2015;16(Suppl 2):S12.CrossRefPubMedPubMedCentral Hsu SD, Huang HY, Chou CH, Sun YM, Hsu MT, Tsou AP. Integrated analyses to reconstruct microRNA-mediated regulatory networks in mouse liver using high-throughput profiling. BMC Genomics. 2015;16(Suppl 2):S12.CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Wu L, Cai C, Wang X, Liu M, Li X, Tang H. MicroRNA-142-3p, a new regulator of RAC1, suppresses the migration and invasion of hepatocellular carcinoma cells. FEBS Lett. 2011;585:1322–30.CrossRefPubMed Wu L, Cai C, Wang X, Liu M, Li X, Tang H. MicroRNA-142-3p, a new regulator of RAC1, suppresses the migration and invasion of hepatocellular carcinoma cells. FEBS Lett. 2011;585:1322–30.CrossRefPubMed
32.
Zurück zum Zitat Xia H, Ooi LL, Hui KM. MiR-214 targets beta-catenin pathway to suppress invasion, stem-like traits and recurrence of human hepatocellular carcinoma. PLoS One. 2012;7:e44206.CrossRefPubMedPubMedCentral Xia H, Ooi LL, Hui KM. MiR-214 targets beta-catenin pathway to suppress invasion, stem-like traits and recurrence of human hepatocellular carcinoma. PLoS One. 2012;7:e44206.CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Hao MW, Liang YR, Liu YF, Liu L, Wu MY, Yang HX. Transcription factor EGR-1 inhibits growth of hepatocellular carcinoma and esophageal carcinoma cell lines. World J Gastroenterol. 2002;8:203–7.CrossRefPubMedPubMedCentral Hao MW, Liang YR, Liu YF, Liu L, Wu MY, Yang HX. Transcription factor EGR-1 inhibits growth of hepatocellular carcinoma and esophageal carcinoma cell lines. World J Gastroenterol. 2002;8:203–7.CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Xiaoyan L, Shengbing Z, Yu Z, Lin Z, Chengjie L, Jingfeng L, et al. Low expression of activating transcription factor 3 in human hepatocellular carcinoma and its clinicopathological significance. Pathol Res Pract. 2014;210:477–81.CrossRefPubMed Xiaoyan L, Shengbing Z, Yu Z, Lin Z, Chengjie L, Jingfeng L, et al. Low expression of activating transcription factor 3 in human hepatocellular carcinoma and its clinicopathological significance. Pathol Res Pract. 2014;210:477–81.CrossRefPubMed
35.
Zurück zum Zitat Yao S, Tian C, Ding Y, Ye Q, Gao Y, Yang N, et al. Down-regulation of Kruppel-like factor-4 by microRNA-135a-5p promotes proliferation and metastasis in hepatocellular carcinoma by transforming growth factor-beta1. Oncotarget. 2016;7:42566–78.CrossRefPubMedPubMedCentral Yao S, Tian C, Ding Y, Ye Q, Gao Y, Yang N, et al. Down-regulation of Kruppel-like factor-4 by microRNA-135a-5p promotes proliferation and metastasis in hepatocellular carcinoma by transforming growth factor-beta1. Oncotarget. 2016;7:42566–78.CrossRefPubMedPubMedCentral
36.
Zurück zum Zitat Teng YC, Shen ZQ, Kao CH, Tsai TF. Hepatocellular carcinoma mouse models: hepatitis B virus-associated hepatocarcinogenesis and haploinsufficient tumor suppressor genes. World J Gastroenterol. 2016;22:300–25.CrossRefPubMedPubMedCentral Teng YC, Shen ZQ, Kao CH, Tsai TF. Hepatocellular carcinoma mouse models: hepatitis B virus-associated hepatocarcinogenesis and haploinsufficient tumor suppressor genes. World J Gastroenterol. 2016;22:300–25.CrossRefPubMedPubMedCentral
37.
Zurück zum Zitat Kanda M, Sugimoto H, Kodera Y. Genetic and epigenetic aspects of initiation and progression of hepatocellular carcinoma. World J Gastroenterol. 2015;21:10584–97.CrossRefPubMedPubMedCentral Kanda M, Sugimoto H, Kodera Y. Genetic and epigenetic aspects of initiation and progression of hepatocellular carcinoma. World J Gastroenterol. 2015;21:10584–97.CrossRefPubMedPubMedCentral
38.
Zurück zum Zitat Chandran UR, Dhir R, Ma C, Michalopoulos G, Becich M, Gilbertson J. Differences in gene expression in prostate cancer, normal appearing prostate tissue adjacent to cancer and prostate tissue from cancer free organ donors. BMC Cancer. 2005;5:45.CrossRefPubMedPubMedCentral Chandran UR, Dhir R, Ma C, Michalopoulos G, Becich M, Gilbertson J. Differences in gene expression in prostate cancer, normal appearing prostate tissue adjacent to cancer and prostate tissue from cancer free organ donors. BMC Cancer. 2005;5:45.CrossRefPubMedPubMedCentral
39.
Zurück zum Zitat Grivennikov SI, Karin M. Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage. Ann Rheum Dis. 2011;70(Suppl 1):i104–8.CrossRefPubMed Grivennikov SI, Karin M. Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage. Ann Rheum Dis. 2011;70(Suppl 1):i104–8.CrossRefPubMed
41.
Zurück zum Zitat Bianco R, Melisi D, Ciardiello F, Tortora G. Key cancer cell signal transduction pathways as therapeutic targets. Eur J Cancer. 2006;42:290–4.CrossRefPubMed Bianco R, Melisi D, Ciardiello F, Tortora G. Key cancer cell signal transduction pathways as therapeutic targets. Eur J Cancer. 2006;42:290–4.CrossRefPubMed
42.
Zurück zum Zitat Selaru FM, Olaru AV, Kan T, David S, Cheng Y, Mori Y, et al. MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3. Hepatology. 2009;49:1595–601.CrossRefPubMedPubMedCentral Selaru FM, Olaru AV, Kan T, David S, Cheng Y, Mori Y, et al. MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3. Hepatology. 2009;49:1595–601.CrossRefPubMedPubMedCentral
43.
Zurück zum Zitat Frankel LB, Christoffersen NR, Jacobsen A, Lindow M, Krogh A, Lund AH. Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J Biol Chem. 2008;283:1026–33.CrossRefPubMed Frankel LB, Christoffersen NR, Jacobsen A, Lindow M, Krogh A, Lund AH. Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J Biol Chem. 2008;283:1026–33.CrossRefPubMed
44.
Zurück zum Zitat Dutto I, Tillhon M, Cazzalini O, Stivala LA, Prosperi E. Biology of the cell cycle inhibitor p21(CDKN1A): molecular mechanisms and relevance in chemical toxicology. Arch Toxicol. 2015;89:155–78.CrossRefPubMed Dutto I, Tillhon M, Cazzalini O, Stivala LA, Prosperi E. Biology of the cell cycle inhibitor p21(CDKN1A): molecular mechanisms and relevance in chemical toxicology. Arch Toxicol. 2015;89:155–78.CrossRefPubMed
45.
Zurück zum Zitat Broude EV, Demidenko ZN, Vivo C, Swift ME, Davis BM, Blagosklonny MV, et al. p21 (CDKN1A) is a negative regulator of p53 stability. Cell Cycle. 2007;6:1468–71.CrossRefPubMed Broude EV, Demidenko ZN, Vivo C, Swift ME, Davis BM, Blagosklonny MV, et al. p21 (CDKN1A) is a negative regulator of p53 stability. Cell Cycle. 2007;6:1468–71.CrossRefPubMed
46.
Zurück zum Zitat Mu X, Pradere JP, Affo S, Dapito DH, Friedman R, Lefkovitch JH, et al. Epithelial transforming growth factor-beta signaling does not contribute to liver fibrosis but protects mice from cholangiocarcinoma. Gastroenterology. 2016;150:720–33.CrossRefPubMed Mu X, Pradere JP, Affo S, Dapito DH, Friedman R, Lefkovitch JH, et al. Epithelial transforming growth factor-beta signaling does not contribute to liver fibrosis but protects mice from cholangiocarcinoma. Gastroenterology. 2016;150:720–33.CrossRefPubMed
Metadaten
Titel
Gene expression, regulation of DEN and HBx induced HCC mice models and comparisons of tumor, para-tumor and normal tissues
verfasst von
Qin Tang
Qi Wang
Qiong Zhang
Sheng-Yan Lin
Yanhong Zhu
Xiangliang Yang
An-Yuan Guo
Publikationsdatum
01.12.2017
Verlag
BioMed Central
Erschienen in
BMC Cancer / Ausgabe 1/2017
Elektronische ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-017-3860-x

Weitere Artikel der Ausgabe 1/2017

BMC Cancer 1/2017 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.